DrugPatentWatch Database Preview
Details for Patent: 10,166,243
Email this page to a colleague
» See Plans and PricingWhich drugs does patent 10,166,243 protect, and when does it expire?
Patent 10,166,243 protects KORLYM and is included in one NDA.
Summary for Patent: 10,166,243
| Title: | Optimizing mifepristone levels for cushing'S patients |
| Abstract: | The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL. |
| Inventor(s): | Belanoff; Joseph (Woodside, CA), Gross; Coleman (Menlo Park, CA) |
| Assignee: | Corcept Therapeutics, Inc. (Menlo Park, CA) |
| Application Number: | 16/146,032 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,166,243 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; |
Drugs Protected by US Patent 10,166,243
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therap | KORLYM | mifepristone | TABLET;ORAL | 202107-001 | Feb 17, 2012 | RX | Yes | Yes | Start Trial | Start Trial | TREATING CUSHING'S SYNDROME | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
